The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2019 | Pathology in the immuno-NGS era: quality and quantity
In the current era of lung cancer diagnosis and management, increasingly featuring more immunotherapy and requiring molecular profiling, pathologists face new challenges. Here, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, UK, discusses this changing field, and addresses the importance of the quality and quantity of samples. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.
